Gene therapy to restore electrophysiological function in heart failure

Bibliography

• Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992;20(2):301-6
   PubMed Web of Science ®Google Scholar
• Tomaselli GF, Beuckelmann DJ, Calkins HG, et al. Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation 1994;90(5):2534-9
   PubMed Web of Science ®Google Scholar
• Estes NAIII, Weinstock J, Wang PJ, et al. Use of antiarrhythmics and implantable cardioverter-defibrillators in congestive heart failure. Am J Cardiol 2003;91(6A):45D-52D
   PubMed Web of Science ®Google Scholar
• Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324(12):781-8
   PubMed Web of Science ®Google Scholar
• Wit AL, Rosen MR. Pathophysiologic mechanisms of cardiac arrhythmias. Am Heart J 1983;106(4 Pt 2):798-811
   PubMed Web of Science ®Google Scholar
• Akar FG, Hajjar RJ. Gene therapies for arrhythmias in heart failure. Pflugers Arch 2014;466(6):1211-17
   PubMed Web of Science ®Google Scholar
• Donahue JK. Gene therapy for ventricular tachyarrhythmias. Gene Ther 2012;19(6):600-5
   PubMed Web of Science ®Google Scholar
• Kober L, Bloch Thomsen PE, Moller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000;356(9247):2052-8
   PubMed Web of Science ®Google Scholar
• Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102(7):748-54
   PubMed Web of Science ®Google Scholar
• Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333(2):77-82
   PubMed Web of Science ®Google Scholar
• Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348(9019):7-12
   PubMed Web of Science ®Google Scholar
• Bostwick JM, Sola CL. An updated review of implantable cardioverter/defibrillators, induced anxiety, and quality of life. Psychiatr Clin North Am 2007;30(4):677-88
   PubMed Web of Science ®Google Scholar
• Gould PA, Krahn AD; Canadian Heart Rhythm Society Working Group on Device A. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA 2006;295(16):1907-11
   PubMed Web of Science ®Google Scholar
• Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999;42(2):270-83
   PubMed Web of Science ®Google Scholar
• Marban E, Robinson SW, Wier WG. Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle. J Clin Invest 1986;78(5):1185-92
   PubMed Web of Science ®Google Scholar
• January CT, Moscucci A. Cellular mechanisms of early afterdepolarizations. Ann N Y Acad Sci 1992;644:23-32
   PubMed Web of Science ®Google Scholar
• Shaw RM, Rudy Y. The vulnerable window for unidirectional block in cardiac tissue: characterization and dependence on membrane excitability and intercellular coupling. J Cardiovasc Electrophysiol 1995;6(2):115-31
   PubMed Web of Science ®Google Scholar
• Akar FG, Rosenbaum DS. Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure. Circ Res 2003;93(7):638-45
   PubMed Web of Science ®Google Scholar
• Cutler MJ, Rosenbaum DS. Explaining the clinical manifestations of T wave alternans in patients at risk for sudden cardiac death. Heart Rhythm 2009;6(3 Suppl):S22-8
   PubMed Web of Science ®Google Scholar
• Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83(1):52-60
   PubMed Web of Science ®Google Scholar
• Murata M, Cingolani E, McDonald AD, et al. Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. Circ Res 2004;95(4):398-405
   PubMed Web of Science ®Google Scholar
• Cingolani E, Ramirez Correa GA, Kizana E, et al. Gene therapy to inhibit the calcium channel {beta} subunit. Physiological consequences and pathophysiological effects in models of cardiac hypertrophy. Circ Res 2007;101(2):166-75
   PubMed Web of Science ®Google Scholar
• Lebeche D, Kaprielian R, del Monte F, et al. In vivo cardiac gene transfer of Kv4.3 abrogates the hypertrophic response in rats after aortic stenosis. Circulation 2004;110(22):3435-43
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Fish J. Electrical heterogeneity within the ventricular wall. Basic Res Cardiol 2001;96(6):517-27
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001;12(2):268-72
   PubMed Web of Science ®Google Scholar
• Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104(4):569-80
   PubMed Web of Science ®Google Scholar
• Mazhari R, Nuss HB, Armoundas AA, et al. Ectopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT interval. J Clin Invest 2002;109(8):1083-90
   PubMed Web of Science ®Google Scholar
• Akar FG, Spragg DD, Tunin RS, et al. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 2004;95(7):717-25
   PubMed Web of Science ®Google Scholar
• Ai X, Pogwizd SM. Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A. Circ Res 2005;96(1):54-63
   PubMed Web of Science ®Google Scholar
• Peters NS, Coromilas J, Severs NJ, et al. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997;95(4):988-96
   PubMed Web of Science ®Google Scholar
• Kim E, Fishman GI. Designer gap junctions that prevent cardiac arrhythmias. Trends Cardiovasc Med 2013;23(2):33-8
   PubMed Web of Science ®Google Scholar
• Greener ID, Sasano T, Wan X, et al. Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction. J Am Coll Cardiol 2012;60(12):1103-10
   PubMed Web of Science ®Google Scholar
• Kanno S, Kovacs A, Yamada KA, et al. Connexin43 as a determinant of myocardial infarct size following coronary occlusion in mice. J Am Coll Cardiol 2003;41(4):681-6
   PubMed Web of Science ®Google Scholar
• Prestia KA, Sosunov EA, Anyukhovsky EP, et al. Increased cell-cell coupling increases infarct size and does not decrease incidence of ventricular tachycardia in mice. Front Physiol 2011;2:1
   Google Scholar
• Boink GJ, Lau DH, Shlapakova IN, et al. SkM1 and Cx32 improve conduction in canine myocardial infarcts yet only SkM1 is antiarrhythmic. Cardiovasc Res 2012;94(3):450-9
   PubMed Web of Science ®Google Scholar
• Lampe PD, Lau AF. Regulation of gap junctions by phosphorylation of connexins. Arch Biochem Biophys 2000;384(2):205-15
   PubMed Web of Science ®Google Scholar
• Protas L, Dun W, Jia Z, et al. Expression of skeletal but not cardiac Na+ channel isoform preserves normal conduction in a depolarized cardiac syncytium. Cardiovasc Res 2009;81(3):528-35
   PubMed Web of Science ®Google Scholar
• Lau DH, Clausen C, Sosunov EA, et al. Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: an in silico, in vivo, in vitro study. Circulation 2009;119(1):19-27
   PubMed Web of Science ®Google Scholar
• Janse MJ. Electrophysiology of arrhythmias. Arch Mal Coeur Vaiss 1999;92(Spec No 1):9-16
   PubMedGoogle Scholar
• Sasano T, McDonald AD, Kikuchi K, et al. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med 2006;12(11):1256-8
   PubMed Web of Science ®Google Scholar
• Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 1997;80(8A):82G-9G
   PubMed Web of Science ®Google Scholar
• O’Rourke B, Kass DA, Tomaselli GF, et al. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. Circ Res 1999;84(5):562-70
   PubMed Web of Science ®Google Scholar
• del Monte F, Hajjar RJ, Harding SE. Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure. Circ Res 2001;88(11):E66-7
   PubMed Web of Science ®Google Scholar
• Zsebo K, Yaroshinsky A, Rudy JJ, et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 2014;114(1):101-8
   PubMed Web of Science ®Google Scholar
• Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009;15(3):171-81
   PubMed Web of Science ®Google Scholar
• Jessup M, Greenberg B, Mancini D, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2010;124(3):304-13
   Web of Science ®Google Scholar
• Cutler MJ, Wan X, Laurita KR, et al. Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circ Arrhythm Electrophysiol 2009;2(6):686-94
   PubMed Web of Science ®Google Scholar
• Cutler MJ, Wan X, Plummer BN, et al. Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to restore electrical stability in the failing heart. Circulation 2013;126(17):2095-104
   Web of Science ®Google Scholar
• Lyon AR, Bannister ML, Collins T, et al. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ Arrhythm Electrophysiol 2011;4(3):362-72
   PubMed Web of Science ®Google Scholar
• Davia K, Bernobich E, Ranu HK, et al. SERCA2A overexpression decreases the incidence of aftercontractions in adult rabbit ventricular myocytes. J Mol Cell Cardiol 2001;33(5):1005-15
   PubMed Web of Science ®Google Scholar
• del Monte F, Lebeche D, Guerrero JL, et al. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci USA 2004;101(15):5622-7
   PubMed Web of Science ®Google Scholar
• Prunier F, Kawase Y, Gianni D, et al. Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation 2008;118(6):614-24
   PubMed Web of Science ®Google Scholar
• Eschenhagen T. G proteins and the heart. Cell Biol Int 1993;17(8):723-49
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376(9744):875-85
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372(9641):817-21
   PubMed Web of Science ®Google Scholar
• Akar FG, Nass RD, Hahn S, et al. Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2007;293(2):H1223-30
   PubMed Web of Science ®Google Scholar
• Moe GW, Armstrong P. Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res 1999;42(3):591-9
   PubMed Web of Science ®Google Scholar
• Cha YM, Redfield MM, Shen WK, et al. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 2004;109(23):2839-43
   PubMed Web of Science ®Google Scholar
• Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002;287(7):883-9
   PubMed Web of Science ®Google Scholar
• Donahue JK, Heldman AW, Fraser H, et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med 2000;6(12):1395-8
   PubMed Web of Science ®Google Scholar
• Bauer A, McDonald AD, Nasir K, et al. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation 2004;110(19):3115-20
   PubMed Web of Science ®Google Scholar
• Lugenbiel P, Thomas D, Kelemen K, et al. Genetic suppression of Galphas protein provides rate control in atrial fibrillation. Basic Res Cardiol 2012;107(3):265
   PubMed Web of Science ®Google Scholar
• Lugenbiel P, Bauer A, Kelemen K, et al. Biological heart rate reduction through genetic suppression of galpha(s) protein in the sinoatrial node. J Am Heart Assoc 2012;1(2):pii: jah3-e000372
   Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014;129(3):e28-e292
   PubMed Web of Science ®Google Scholar
• Khan AR, Khan S, Sheikh MA, et al. Catheter ablation and antiarrhythmic drug therapy as first- or second-line therapy in the management of atrial fibrillation: systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2014;7(5):853-60
   PubMed Web of Science ®Google Scholar
• Soucek R, Thomas D, Kelemen K, et al. Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. Heart Rhythm 2012;9(2):265-72
   PubMed Web of Science ®Google Scholar
• Amit G, Kikuchi K, Greener ID, et al. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation 2010;121(21):2263-70
   PubMed Web of Science ®Google Scholar
• Igarashi T, Finet JE, Takeuchi A, et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 2012;125(2):216-25
   PubMed Web of Science ®Google Scholar
• Iwasaki YK, Nishida K, Kato T, et al. Atrial fibrillation pathophysiology: implications for management. Circulation 2011;124(20):2264-74
   PubMed Web of Science ®Google Scholar
• Aime-Sempe C, Folliguet T, Rucker-Martin C, et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999;34(5):1577-86
   PubMed Web of Science ®Google Scholar
• Trappe K, Thomas D, Bikou O, et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J 2013;34(2):147-57
   PubMed Web of Science ®Google Scholar
• Saxon LA, Stevenson WG, Middlekauff HR, et al. Increased risk of progressive hemodynamic deterioration in advanced heart failure patients requiring permanent pacemakers. Am Heart J 1993;125(5 Pt 1):1306-10
   PubMed Web of Science ®Google Scholar
• Thambo JB, Bordachar P, Garrigue S, et al. Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 2004;110(25):3766-72
   PubMed Web of Science ®Google Scholar
• Spragg DD, Leclercq C, Loghmani M, et al. Regional alterations in protein expression in the dyssynchronous failing heart. Circulation 2003;108(8):929-32
   PubMed Web of Science ®Google Scholar
• Aiba T, Hesketh GG, Barth AS, et al. Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation 2009;119(9):1220-30
   PubMed Web of Science ®Google Scholar
• Eberhardt F, Bode F, Bonnemeier H, et al. Long term complications in single and dual chamber pacing are influenced by surgical experience and patient morbidity. Heart 2005;91(4):500-6
   PubMed Web of Science ®Google Scholar
• Rosen MR, Robinson RB, Brink PR, et al. The road to biological pacing. Nat Rev 2010;8(11):656-66
   Google Scholar
• Miake J, Marban E, Nuss HB. Biological pacemaker created by gene transfer. Nature 2002;419(6903):132-3
   PubMed Web of Science ®Google Scholar
• Robinson RB, Brink PR, Cohen IS, et al. I(f) and the biological pacemaker. Pharmacol Res 2006;53(5):407-15
   PubMed Web of Science ®Google Scholar
• Plotnikov AN, Bucchi A, Shlapakova I, et al. HCN212-channel biological pacemakers manifesting ventricular tachyarrhythmias are responsive to treatment with I(f) blockade. Heart Rhythm 2008.5(2):282-8
   Google Scholar
• Rosen MR, Brink PR, Cohen IS, et al. Biological pacemakers based on I(f). Med Biol Eng Comput 2007;45(2):157-66
   PubMed Web of Science ®Google Scholar
• Plotnikov AN, Sosunov EA, Qu J, et al. Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation 2004;109(4):506-12
   PubMed Web of Science ®Google Scholar
• Qu J, Plotnikov AN, Danilo PJr, et al. Expression and function of a biological pacemaker in canine heart. Circulation 2003;107(8):1106-9
   PubMed Web of Science ®Google Scholar
• Bucchi A, Plotnikov AN, Shlapakova I, et al. Wild-type and mutant HCN channels in a tandem biological-electronic cardiac pacemaker. Circulation 2006;114(10):992-9
   PubMed Web of Science ®Google Scholar
• Tse HF, Xue T, Lau CP, et al. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation 2006;114(10):1000-11
   PubMed Web of Science ®Google Scholar
• Ruhparwar A, Kallenbach K, Klein G, et al. Adenylate-cyclase VI transforms ventricular cardiomyocytes into biological pacemaker cells. Tissue Eng Part A 2010;16(6):1867-72
   PubMed Web of Science ®Google Scholar
• Boink GJ, Nearing BD, Shlapakova IN, et al. Ca(2+)-stimulated adenylyl cyclase AC1 generates efficient biological pacing as single gene therapy and in combination with HCN2. Circulation 2012;126(5):528-36
   PubMed Web of Science ®Google Scholar
• Cingolani E, Yee K, Shehata M, et al. Biological pacemaker created by percutaneous gene delivery via venous catheters in a porcine model of complete heart block. Heart Rhythm 2012;9(8):1310-18
   PubMed Web of Science ®Google Scholar
• Boink GJ, Robinson RB. Gene therapy for restoring heart rhythm. J Cardiovasc Pharmacol Ther 2014;19(5):426-38
   PubMed Web of Science ®Google Scholar
• Boink GJ, Duan L, Nearing BD, et al. HCN2/SkM1 gene transfer into canine left bundle branch induces stable, autonomically responsive biological pacing at physiological heart rates. J Am Coll Cardiol 2013;61(11):1192-201
   PubMed Web of Science ®Google Scholar
• Hoogaars WM, Engel A, Brons JF, et al. Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria. Genes Dev 2007;21(9):1098-112
   PubMed Web of Science ®Google Scholar
• Bakker ML, Boink GJ, Boukens BJ, et al. T-box transcription factor TBX3 reprogrammes mature cardiac myocytes into pacemaker-like cells. Cardiovasc Res 2012;94(3):439-49
   PubMed Web of Science ®Google Scholar
• Kapoor N, Liang W, Marban E, et al. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat Biotechnol 2013;31(1):54-62
   PubMed Web of Science ®Google Scholar
• Hu YF, Dawkins JF, Cho HC, et al. Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci Transl Med 2014;6(245):245ra94
   PubMed Web of Science ®Google Scholar
• Rosen MR. Gene therapy and biological pacing. N Engl J Med 2014;371(12):1158-9
   PubMed Web of Science ®Google Scholar
• Greener I, Donahue JK. Gene therapy strategies for cardiac electrical dysfunction. J Mol Cell Cardiol 2011;50(5):759-65
   PubMed Web of Science ®Google Scholar
• Gwathmey JK, Yerevanian A, Hajjar RJ. Targeting sarcoplasmic reticulum calcium ATPase by gene therapy. Hum Gene Ther 2013;24(11):937-47
   PubMed Web of Science ®Google Scholar
• Scimia MC, Gumpert AM, Koch WJ. Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther 2014;14(2):183-95
   PubMed Web of Science ®Google Scholar
• Schram G, Pourrier M, Melnyk P, et al. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res 2002;90(9):939-50
   PubMed Web of Science ®Google Scholar
• Akar FG, Xiong W, Juang GJ, et al. Molecular mechanisms underlying potassium current down-regulation in heart failure. Circulation 2003;108(17):82
   Web of Science ®Google Scholar